Skip to main content
Premium Trial:

Request an Annual Quote

Gregory Phelps, Gordon Brunner, John Reed

Premium

Ardais has named Gregory Phelps CEO, the company said Jan. 20.

Phelps, 53, comes to Ardais from Dyax, where he was vice chairman and was responsible for corporate development.

“Greg is well known as an industry leader with strong business management skills, extensive operations experience, knowledge of R&D management, and expertise in the development of new products and new businesses on a global scale,” said Ardais’ Chairman Jeffrey Otten.


Third Wave Technologies has appointed Procter & Gamble veteran Gordon Brunner, 64, to its board of directors, the company announced Jan. 21.

Gordon, whose positions at P&G included senior VP, chief technology officer, head of worldwide research, and a place on the board, said “there is a global need for genetic testing products.”


Genome BioSciences has tapped John Reed to sit on its scientific advisory board, the company said Jan. 21.

Reed, 44, is president of the Burnham Institute and joins Paul Hasty of the University of Texas, San Antonio, who was the first SAB member appointed this year.

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.